Intestinal failure–associated liver disease (IFALD) is a major concern in the management of pediatric intestinal failure, representing a leading cause of ...

In 1980, Ludwig and colleagues described the histologic features of a newly identified chronic liver condition referred to as nonalcoholic steatohepatitis (NASH) and noted that the majority of the ...

When most people think about liver disease, they think about alcohol or hepatitis. What many don’t realize is that the most common cause of chronic liver disease in the United States today has nothing ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

With the rising epidemic of obesity, metabolic syndrome, and type 2 diabetes mellitus in China, metabolic dysfunction-associated non-alcoholic fatty liver disease has become the most prevalent chronic ...

A research team affiliated with UNIST has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to ...

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), the agency announced. The glucagon-like peptide-1 ...

What Is Metabolic Dysfunction-Associated Steatohepatitis? Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of liver disease. MASH occurs when fat accumulates in liver cells. Plenty ...

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...